179 related articles for article (PubMed ID: 16935001)
1. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C; Felsher DW
Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
[TBL] [Abstract][Full Text] [Related]
2. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
3. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
4. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
5. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
6. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models.
Felsher DW
Cell Cycle; 2006 Aug; 5(16):1808-11. PubMed ID: 16929172
[TBL] [Abstract][Full Text] [Related]
7. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
8. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW
Nature; 2004 Oct; 431(7012):1112-7. PubMed ID: 15475948
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
10. Tumor dormancy and oncogene addiction.
Felsher DW
APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
[TBL] [Abstract][Full Text] [Related]
11. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.
Shachaf CM; Felsher DW
Cancer Res; 2005 Jun; 65(11):4471-4. PubMed ID: 15930260
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
[TBL] [Abstract][Full Text] [Related]
13. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
14. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
[TBL] [Abstract][Full Text] [Related]
15. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents.
Grippo PJ; Sandgren EP
Int J Cancer; 2012 Sep; 131(5):1243-8. PubMed ID: 22024988
[TBL] [Abstract][Full Text] [Related]
16. Myc lacks E2F1's ability to suppress skin carcinogenesis.
Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
[TBL] [Abstract][Full Text] [Related]
17. Conditionally MYC: insights from novel transgenic models.
Arvanitis C; Felsher DW
Cancer Lett; 2005 Aug; 226(2):95-9. PubMed ID: 16039948
[TBL] [Abstract][Full Text] [Related]
18. Oncogene addiction: sometimes a temporary slavery.
Jonkers J; Berns A
Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
[TBL] [Abstract][Full Text] [Related]
19. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.
Lewis BC; Klimstra DS; Varmus HE
Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205
[TBL] [Abstract][Full Text] [Related]
20. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
